Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
23:52
Sorin Grindeanu, on the appointment of Siegfried Mureșan as prime minister: “He will go down gloriously in Parliament”
23:37
Nicușor Dan is said to have proposed Siegfried Mureșan for the position of prime minister without informing the coalition leaders beforehand (sources)
23:22
Dominic Fritz denies having told Nicușor Dan: “This thing with Romania is your problem; the party is my problem”
23:16
Donald Trump withdrew his proposal to lead ICE
22:53
Mark Carney Rejects U.S. Pressure and Backs Closer Ties Between Canada and the EU
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
